Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2017-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT06599229

Hypertrophic Cardiomyopathy (HCM)

NOT_YET_RECRUITING

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

NCT00001632

Healthy Hypertrophic Cardiomyopathy Left Ventricular Hypertrophy

COMPLETED

Handheld Echocardiography in Clinical Practice

NCT01558518

Cardiovascular Disease

COMPLETED

Study of Myocardial Deformation Parameters in Patients With Hypertrophic Cardiomyopathy

NCT04112511

Hypertrophic Cardiomyopathy

COMPLETED

Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation

NCT01572220

Chest Pain Symptomatic Ischemic Equivalent

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at Mayo Clinic will be eligible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with HCM

All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.

Noncontrast echocardiography

Intervention Type PROCEDURE

Contrast Echocardiography

Intervention Type PROCEDURE

Cardiac magnetic resonance imaging

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Noncontrast echocardiography

Intervention Type PROCEDURE

Contrast Echocardiography

Intervention Type PROCEDURE

Cardiac magnetic resonance imaging

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinically and echocardiographically defined hypertrophic cardiomyopathy.
2. Clinically indicated transthoracic echocardiography as part of the medical evaluation.
3. No contradiction to administration of ultrasonic echocardiography contrast.
4. Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
5. No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
6. Age 18 years and older